Lead Product(s) : Endotoxin
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma
Details : Endotoxin is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Eosinophilia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 21, 2024
Lead Product(s) : Endotoxin
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable